Clinical Cancer Research, Vol 3, Issue 9 1507-1518, Copyright © 1997 by American Association for Cancer Research

ARTICLES

Urinary proton magnetic resonance studies of early ifosfamide-induced nephrotoxicity and encephalopathy

PJ Foxall, JM Singer, JM Hartley, GH Neild, M Lapsley, JK Nicholson and RL Souhami
Institute of Urology and Nephrology, University College London Medical School, University of London, London, United Kingdom.

Ifosfamide is an oxazophosphorine widely used in the treatment of cancer in children and adults. Nephrotoxicity and neurotoxicity are major side effects. The aim of this study was to use high-resolution proton nuclear magnetic resonance (1H NMR) spectroscopy of urine to identify novel biochemical markers of ifosfamide-induced toxicity. Urine samples were collected from 10 nonencephalopathic patients (who had not previously received nephrotoxic chemotherapy) immediately prior to the first ifosfamide dose and at timed intervals for up to four treatment cycles. The findings were compared with those for urine samples collected from five patients during acute encephalopathic episodes. 1H NMR urinalysis identified a series of characteristic time-related changes in the excretion profiles of low molecular weight endogenous metabolites during ifosfamide therapy. These changes included a decreased excretion of hippurate and an increased excretion of glycine, histidine, glucose, lactate, and trimethylamine-N-oxide. Two nonencephalopathic patients had marked but transient glutaric or adipic aciduria during the second cycle of ifosfamide treatment. Urinary retinol-binding protein rose acutely after each treatment cycle but usually returned to baseline levels. Maximum renal toxicity was observed by the fourth treatment cycle. The ratio of the urinary excretion of the uroprotectant mesna (active form) to dimesna (inactive form) correlated with the degree of renal toxicity. For the encephalopathic patients, the ifosfamide-induced changes in the urinary low molecular weight metabolite profile were similar to those for the nonencephalopathic group. In contrast to previous reports, none of the encephalopathic group developed glutaric aciduria, and i.v. methylene blue did not reverse neurotoxicity in the two patients who received it. The results suggest that ifosfamide nephrotoxicity involves both cortical and medullary regions of the nephron and that the urinary mesna:dimesna ratio may be important in assessing the degree of cytoprotection. This study demonstrates that 1H NMR can provide novel biochemical information on ifosfamide-induced toxicity and will be of value in the optimization of ifosfamide therapy.

This article has been cited by other articles:

				A. Vilasi, P. R. Cutillas, A. D. Maher, S. F. M. Zirah, G. Capasso, A. W. G. Norden, E. Holmes, J. K. Nicholson, and R. J. Unwin Combined proteomic and metabonomic studies in three genetic forms of the renal Fanconi syndrome Am J Physiol Renal Physiol, August 1, 2007; 293(2): F456 - F467. [Abstract] [Full Text] [PDF]

				A. G. Renwick The Safety Testing of Amino Acids J. Nutr., June 1, 2003; 133(6): 2031S - 2033. [Abstract] [Full Text] [PDF]

				J.-Y. Chatton, J. R. Idle, C. B. Vagbo, and P. J. Magistretti Insights into the Mechanisms of Ifosfamide Encephalopathy: Drug Metabolites Have Agonistic Effects on alpha -Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid (AMPA)/Kainate Receptors and Induce Cellular Acidification in Mouse Cortical Neurons J. Pharmacol. Exp. Ther., December 1, 2001; 299(3): 1161 - 1168. [Abstract] [Full Text] [PDF]